#USA #San Diego #Class Action #Geron Corporation #Rytelo

Geron Corporation Investors Encouraged to Act

In light of recent developments, investors who have sustained substantial financial losses with Geron Corporation (NASDAQ: GERN) are being urged to participate in a class action lawsuit against the company. This opportunity is being presented by the law firm Robbins Geller Rudman & Dowd LLP, specializing in representing investors in securities fraud cases.

Key Details of the Class Action

Uniting investors under the Dabestani v. Geron Corporation lawsuit, which has been filed in the Northern District of California, the class period spans from February 28, 2024, to February 25, 2025. Those who acquired Geron securities during this timeframe have until May 12, 2025, to apply for the role of lead plaintiff in the case.

The allegations in the suit assert that Geron Corporation and certain executives misled investors about the company's performance and growth prospects, particularly regarding their main product, the telomerase inhibitor Imetelstat, sold under the brand name Rytelo. Investors claim they were given an optimistic portrayal of product launches and projected revenues that did not stand up to scrutiny once actual market conditions were revealed.

Allegations Against Geron

1. Misleading Revenue Projections: The lawsuit states that the defendants created a misleading impression of their understanding of Geron’s revenue outlook while downplaying the risks associated with market fluctuations and seasonality.
2. Discrepant Performance Reports: The class action emphasizes that optimistic reports about Rytelo's success were misleading. Factors such as intense competition and a lack of awareness significantly impacted the product's performance upon launch, contradicting statements made by Geron’s executives.
3. Stock Price Drop: Following a disheartening announcement on February 26, 2025, revealing a stark decline in Rytelo's growth—primarily due to competitive pressures and limited market exposure—Geron’s stock price plummeted by over 32%.

The Role of the Lead Plaintiff

The Private Securities Litigation Reform Act of 1995 allows any investor who acquired Geron Corporation securities during the specified class period to seek appointment as the lead plaintiff. This individual will generally be the one with the most substantial financial stake in the lawsuit who can adequately represent the interests of the broader class. The lead plaintiff holds crucial responsibilities, directing the case and selecting legal counsel to argue on behalf of all involved investors. Importantly, participating as the lead plaintiff does not affect one's potential recovery from a settlement.

About Robbins Geller

Robbins Geller Rudman & Dowd LLP is renowned as a leading law firm representing investors in securities litigation and has secured more than $2.5 billion for clients in 2024 alone. The firm's track record includes landmark cases resulting in substantially large recoveries for investors, thus validating their strong presence in securities-related class actions.

As Geron Corporation investors weigh their options, this class action offers a potentially significant avenue for recovery. Investors seeking to learn more or wishing to file for lead plaintiff status can find additional information on the Robbins Geller website or reach out directly to attorneys specializing in these cases.

Take Action

For more details on how to participate and safeguard your investment interests, please visit the following link: Robbins Geller's Geron Class Action Website.
Given the complexities of securities litigation, prompt action is recommended to ensure that your voice is heard within this crucial legal endeavor.